Orexo AB announced new topline results of 2 clinical trials with a combination of buprenorphine and naloxone for buprenorphine induction and plans to pursue approval of an expanded label in the US. Medscape Medical News (Source: Medscape Medical News Headlines)
MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.
